CHECK the NEW financial results of RxSight!!
Preliminary Unaudited Results
Preliminary unaudited fourth quarter 2021 revenue is expected to be approximately $8.4 million, representing growth of approximately 71% compared to the prior year period, driven by:
Sale of 45 Light Delivery Devices (LDD™s), expanding the installed base to 206 LDDs as of December 31, 2021; and
Sale of 2,959 Light Adjustable Lenses (LAL®s).
Preliminary unaudited 2021 fiscal year revenue is expected to be approximately $22.6 million, representing growth of approximately 54% compared to the prior year, driven by:
Sale of 114 LDDs; and
Sale of 8,328 LALs.
Preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2021, is expected to be approximately $159.3 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
